Cognition Therapeutics (NASDAQ:CGTX) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Cognition Therapeutics (NASDAQ:CGTX) issued its earnings results on Thursday. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03, FiscalAI reports.

Here are the key takeaways from Cognition Therapeutics’ conference call:

• Cognition says it has aligned with the FDA on a planned Phase III trial of zervimesine for mild-to-moderate DLB, with one pivotal study potentially sufficient, subject to FDA review of the completed data. The company aims to start the trial in mid-2027.
• The planned trial will use hallucinations and delusions, measured by the NPI-2, as its primary endpoint, with daily living activities as a key secondary endpoint. Management cited favorable Phase II SHIMMER results across DLB symptoms, but the Phase III study will need to confirm whether the treatment slows disease progression.
• The company is evaluating funding options for the DLB trial. Management said the revised design requires less than half the roughly 750 participants initially contemplated, but did not provide a new trial cost; current cash is expected to fund operations only into the fourth quarter of 2027.
• The 545-participant START Phase II study in mild cognitive impairment and early Alzheimer’s disease is fully enrolled and funded by the NIA, with top-line results expected in the second half of 2027. Management said baseline data have not yet been analyzed for comparison with the prior SHINE study.

Cognition Therapeutics Trading Up 8.1%

NASDAQ CGTX traded up $0.05 during trading on Friday, hitting $0.69. 282,194 shares of the company’s stock were exchanged, compared to its average volume of 605,701. The company has a market cap of $65.33 million, a PE ratio of -4.58 and a beta of 1.84. Cognition Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $1.82. The stock’s 50 day moving average price is $0.88 and its two-hundred day moving average price is $1.05.

Analysts Set New Price Targets

Several analysts recently issued reports on CGTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Monday, September 21st. HC Wainwright restated a “buy” rating on shares of Cognition Therapeutics in a research report on Monday, October 5th. Finally, Wall Street Zen cut Cognition Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Cognition Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $3.33.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration.

Cognition Therapeutics’ lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex.